摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-溴-2,3-二氟苯甲醚 | 261762-35-0

中文名称
5-溴-2,3-二氟苯甲醚
中文别名
2,3-二氟-5-溴苯甲醚;5-溴-1,2-二氟-3-甲氧基苯
英文名称
5-bromo-1,2-difluoro-3-methoxybenzene
英文别名
5-bromo-2,3-difluoroanisole
5-溴-2,3-二氟苯甲醚化学式
CAS
261762-35-0
化学式
C7H5BrF2O
mdl
——
分子量
223.017
InChiKey
UDTVFZBQFYOZST-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    33-35°C
  • 沸点:
    193.7±35.0 °C(Predicted)
  • 密度:
    1.615±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2909309090
  • 危险性防范说明:
    P305+P351+P338
  • 危险性描述:
    H315,H319

SDS

SDS:5666d8754009483c12cf2a6c139a9ee6
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Bromo-2,3-difluoroanisole
Synonyms: 5-Bromo-1,2-difluoro-3-methoxybenzene

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-2,3-difluoroanisole
CAS number: 261762-35-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H5BrF2O
Molecular weight: 223.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-溴-2,3-二氟苯甲醚三溴化硼 作用下, 以 二氯甲烷 为溶剂, 反应 2.0h, 以79%的产率得到5-bromo-1,2-difluoro-3-(methoxymethoxy)benzene
    参考文献:
    名称:
    [EN] HSD17B13 INHIBITORS AND USES THEREOF
    [FR] INHIBITEURS DE HSD17B13 ET LEURS UTILISATIONS
    摘要:
    本文描述了一些作为HSD17B13抑制剂的化合物,制备这些化合物的方法,包含这些化合物的药物组合物和药物,以及利用这些化合物治疗与HSD17B13活性相关的疾病、病症或障碍的方法。
    公开号:
    WO2022072512A1
  • 作为产物:
    描述:
    5-溴-2,3-二氟苯酚碘甲烷potassium carbonate 作用下, 以 丙酮 为溶剂, 反应 4.0h, 生成 5-溴-2,3-二氟苯甲醚
    参考文献:
    名称:
    Cinnamide compound
    摘要:
    本发明涉及一种由式(I)表示的化合物:(其中Ar1代表可以被1到3个取代基取代的咪唑基团;Ar2代表可以被1到3个取代基取代的吡啶基团、嘧啶基团或苯基;X1代表(1)-C≡C-或(2)可以被取代的双键等;R1和R2代表,例如,可以被取代的C1-6烷基或C3-8环烷基等)或其药理学上可接受的盐,并且用作药物剂。本发明的目的是寻找一种治疗或预防由Aβ引起的疾病的药剂。根据本发明,可以提供治疗或预防由Aβ引起的疾病的药剂。
    公开号:
    US20060004013A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED CYCLOPROPYL-2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME<br/>[FR] COMPOSÉS DE CYCLOPROPYL-2,2'-BIPYRIMIDINYL SUBSTITUÉS, ANALOGUES DE CEUX-CI, ET PROCÉDÉS LES UTILISANT
    申请人:ARBUTUS BIOPHARMA INC
    公开号:WO2021025976A1
    公开(公告)日:2021-02-11
    The present disclosure includes novel substituted cyclopropyl-2,2'-bipyrimidinyl compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.
    本公开涵盖了新型的取代环丙基-2,2'-双嘧啶基化合物,以及包含这些化合物的组合物,可用于治疗或预防患者体内的乙型肝炎病毒(HBV)感染和/或丙型肝炎病毒(HDV)感染。
  • [EN] TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS<br/>[FR] TÉTRAHYDROPYRIDOPYRIMIDINES ET TÉTRAHYDROPYRIDOPYRIDINES COMME INHIBITEURS D'AG HBS (ANTIGÈNE DE SURFACE DU VIRUS DE L'HÉPATITE B) ET PRODUCTION D'ADN DE VHB POUR LE TRAITEMENT D'INFECTIONS PAR LE VIRUS DE L'HÉPATITE B
    申请人:HOFFMANN LA ROCHE
    公开号:WO2016177655A1
    公开(公告)日:2016-11-10
    The present invention provides tetrahydropyridopyrimidines and tetrahydropyridopyridines having the general formula (I) wherein R1, R2, U, W, X, Y and Z are as described herein, as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment and prophylaxis of hepatitis B virus infections.
    本发明提供了具有一般式(I)的四氢吡啶嘧啶和四氢吡啶吡啶,其中R1、R2、U、W、X、Y和Z如本文所述,作为乙型肝炎病毒表面抗原(HBsAg)和HBV DNA的抑制剂,用于治疗和预防乙型肝炎病毒感染。
  • CYCLOALKANE-1,3-DIAMINE DERIVATIVE
    申请人:Daiichi Sankyo Company, Limited
    公开号:US20210269454A1
    公开(公告)日:2021-09-02
    The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Ring Q 1 , W, m and n are each as defined in the description.
    本发明提供了一种具有对menin和MLL蛋白相互作用抑制作用的化合物或其药学上可接受的盐。该化合物由式(1)表示,或其药学上可接受的盐。 在式(1)中,虚线圈,R1,R2,R3,R4,R5,R6,R7,R8,环Q1,W,m和n的定义如描述中所述。
  • [EN] 1 -HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS<br/>[FR] 1-HYDROXY-BENZOOXABOROLES COMME AGENTS ANTIPARASITAIRES
    申请人:LILLY CO ELI
    公开号:WO2014149793A1
    公开(公告)日:2014-09-25
    Provided are compounds useful for controlling endoparasites both in animals and agriculture. Further provided are methods for controlling endoparasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling endoparasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. The claimed compounds are described by the following Markush formula:A typical example for a compound according to above formula is: A typical example for a compound according to above formula is:
    提供了一些在动物和农业中控制内寄生虫的化合物。此外,还提供了一种通过向动物施用上述化合物或其药学上可接受的盐的有效量来控制动物内寄生虫侵染的方法,以及使用上述化合物或其可接受的盐以及可接受的载体来控制内寄生虫侵染的配方。所述的化合物由以下Markush公式描述:根据上述公式的化合物的典型示例是:
  • [EN] COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS<br/>[FR] COMPOSÉS UTILES DANS LE TRAITEMENT DE TROUBLES ASSOCIÉS À RAS MUTANT
    申请人:UNIV OXFORD INNOVATION LTD
    公开号:WO2019234405A1
    公开(公告)日:2019-12-12
    The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
    本发明涉及式I所定义的化合物,以及它们的盐和溶剂化物。(I)本发明还涉及包含式(I)化合物的药物组合物,以及式(I)化合物用于治疗增殖性疾病,如癌症,以及其它涉及抑制RAS效应蛋白-蛋白相互作用的疾病或状况。
查看更多